Form 4: Athira Pharma's Chief Scientific Officer, Kevin Church, Acquires 110,000 Restricted Stock Units and Stock Options

Kevin Church, Chief Scientific Officer of Athira Pharma, acquired 110,000 Restricted Stock Units and 110,000 stock options on October 1, 2024, according to a recent SEC filing.

Summary

• On October 1, 2024, Kevin Church, the Chief Scientific Officer of Athira Pharma, acquired 110,000 Restricted Stock Units (RSUs) and 110,000 stock options.
• The RSUs represent a contingent right to receive one share of Athira Pharma's common stock each.
• One-third of the RSUs will vest on each of December 31, 2024, June 30, 2025, and December 31, 2025, contingent upon continued service.
• Similarly, one-third of the shares subject to the stock options will vest on the same dates, also contingent upon continued service.
• The stock options have an exercise price of $0.4499 and expire on September 30, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, suggesting stability and alignment of interests. The vesting schedule indicates a long-term commitment, which is generally viewed positively.

Positives

• The acquisition of RSUs and stock options by a key executive like the Chief Scientific Officer can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedule, tied to continued service, incentivizes the executive to remain with the company and contribute to its success.

Future Outlook

The vesting schedule of the RSUs and stock options suggests an expectation of continued service and contribution from the Chief Scientific Officer over the next year and a half.

Industry Context

Stock options and RSU grants are common compensation tools used in the biotechnology industry to attract and retain key talent, aligning their interests with those of the shareholders.

Comparison to Industry Standards

• Stock option and RSU grants are a standard practice in the biotech industry.
• Companies like Biogen, Amgen, and Gilead Sciences routinely use equity-based compensation to incentivize their executives.
• The vesting schedules and exercise prices are typically structured to align with long-term company performance and shareholder value creation.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning executive interests with company performance.
• Employees may see this as a sign of stability and investment in key personnel.

Key Dates